Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability (2023 - 2025)

Iovance Biotherapeutics has reported Non-Current Deferred Tax Liability over the past 3 years, most recently at $31.8 million for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $31.8 million for Q4 2025, down 1.51% from a year ago — trailing twelve months through Dec 2025 was $31.8 million (down 1.51% YoY), and the annual figure for FY2025 was $31.8 million, down 1.51%.
  • Non-Current Deferred Tax Liability for Q4 2025 was $31.8 million at Iovance Biotherapeutics, up from $31.7 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for IOVA hit a ceiling of $34.7 million in Q2 2025 and a floor of $17.3 million in Q4 2023.
  • Median Non-Current Deferred Tax Liability over the past 3 years was $31.8 million (2025), compared with a mean of $28.0 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 86.29% in 2024 and later fell 4.02% in 2025.
  • Iovance Biotherapeutics' Non-Current Deferred Tax Liability stood at $17.3 million in 2023, then surged by 86.29% to $32.3 million in 2024, then fell by 1.51% to $31.8 million in 2025.
  • The last three reported values for Non-Current Deferred Tax Liability were $31.8 million (Q4 2025), $31.7 million (Q3 2025), and $34.7 million (Q2 2025) per Business Quant data.